Abstract-The effect of idebenone (CV-261 9
Abstract-The effect of idebenone (CV-261 9), 6-(10-hydroxydecyl)-2,3-dimethoxy 5-methyl-l,4-benzoquinone, on 5-hydroxyindoles in the dorsal hippocampus of rats was investigated by using in vivo differential pulse voltammetry. CV-2619 (100 mg/kg, i.p.) produced a large increase in oxidation current at 280 mV (peak 2) in the dorsal hippocampus.
The increase was statistically significant at 20 and 30 min after the administration.
5-Hydroxytryptophan (150 mg/kg, i.p.) also caused a marked increase in peak 2, which was clearly inhibited by the treatment with pargyline (50 mg/kg, i.p.). Thus, the increase in peak 2 induced by CV-2619 seems to be associated with an increase in the 5-HT metabolite 5-hydroxy indoleacetic acid and also partly with an increase in 5-HT.
Idebenone
(CV-2619), 6-(10-hydroxy decyl) -2,3-dimethoxy-5-methyl-l,4-benzo quinone, has unique pharmacological actions such as inhibition of lipid peroxidation in the cerebral homogenate (1) and im provement of cerebral energy metabolism in rats with experimental ischemia (2). Narumi et al. (3) have found in their neurochemical study on cerebral monoamine metabolism that CV-2619 stimulates 5-HT turnover in the various brain regions of rats.
In this experiment, in vivo differential pulse voltammetry (DPV) was applied to provide additional evidence that CV-2619 stimulates the release of 5-HT in the dorsal hippocampus of rats. Cushman (4) and a combination electrode (Expol® R-C, Shionogi, consisting of Ag/ AgCI reference and stainless steel auxiliary electrode), cemented on the frontal skull. Before and after the experiment, each electrode was calibrated in a standard solution of 5-HT (5 /tM). In the recording of DPV, the following conditions were applied: potential range from -200 mV to +600 mV/ reference, scan rate 50 mV/sec, pulse of 50 mV in amplitude and 41.6 msec of duration. The height of oxidation current peak 2 detected at 280 mV was measured once every 10 min before and after the drug administration.
The amplitude change in the current was indicated as relative values (%) to the average value of 3-4 consecutive recordings before drug administration. Statistical comparison between different treatments was made by the x2-test.
Voltammograms recorded from the dorsal hippocampus usually yielded two oxidation peaks. Peak 1 (+120 mV) corresponded to catechols and peak 2 (+280 mV) to indoles (in vitro experiment).
As shown in Fig. 1 , CV-2619 in a dose of 100 mg/kg, i.p., but not 30 mg/kg, produced a large increase in oxidation peak 2. The increase was apparent 10 and 50 min after the administration and significant (P<0.05 vs. vehicle administered group) at 20 and 30 min, and returned gradually to the pre-drug level. The time course effect of CV-2619 was consistent with our previous results on 5-HT metabolism in the rat brain (3). 
5-Hydroxytryptophan
(5-HTP, 150 mg/kg, i.p.) also caused a marked increase in peak 2 as shown in Fig. 2 . The increase was sig nificant 20 min after the administration and reached a plateau level from 60 to 120 min. These voltammograms changes indicate that CV-2619 stimulates the release of 5-HT in the hippocampal extracellular space. The next experiment was designed to examine which indoles contributed to the observed increase in peak 2, since both 5-HT and its major metabolite 5-hydroxyindoleacetic acid (5-HIAA) were electroactive and have the same oxidation potential. When the mono amine oxidase inhibitor pargyline (50 mg/kg, i.p.) was given 30 min after the adminis tration of 5-HTP, remarkable depression in peak 2 was observed, although pargyline itself had no significant effect on it. Pargyline inhibits the metabolism of 5-HT to 5-HIAA, resulting in an increase in 5HT content in the intra and extracellular compartments and a decrease in extracellular 5-HIAA content (5, 6) . Thus, the increase in peak 2 by 5-HTP is mainly related to an increase in 5-HIAA.
It has been reported that CV-2619 has no significant effect on the levels of catechol amines and their metabolites and the levels of 5-HT in brain regions, while it (100 mg/ kg, i.p.) markedly increases the levels of 5 HIAA in many brain regions including the hippocampus, but not in a dose of 30 mg/ kg (3). Therefore, the increase in peak 2 observed in the present study contributes greatly to the increase in 5-H IAA and probably partly contribates to the increase in 5-HT.
Kennet and Joseph (7) suggest that extraneuronal 5-HIAA and 5-HT contribute approximately equally to the hippocampal electrochemical signal. Cespuglio et al. (8) and Rivot et al. (9) reported that 5-HIAA was responsible for the signal detected by carbon fiber electrode to a considerable extent in the striatum and in the dorsal horn of the spinal cord in the anesthetized rats.
The 5-HT fibers originating from the dorsal and median raphe nuclei have a differential projection: the primary origin of hippocampal 5-HT appears to be chiefly in the median raphe nucleus (10), while the striatum and other parts of the forebrain receive the projection mainly from the dorsal raphe nucleus (11). The electrical lesion of the median raphe nucleus induced the impair ments of acquisition, retention and extinction of one-way avoidance task in rats (12). In addition to cholinergic and noradrenergic systems, the 5-HT system has been suggested to have a role in memory function (13, 14) and moreover mood regulation (15). Our present and previous pharmacological data suggest that CV-2619 may be useful for improvement of cognitive and emotional disorders in patients with cerebrovascular disturbance. 
